Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bayer AG is conducting a study titled ‘An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria.’ The study aims to evaluate the long-term safety and efficacy of finerenone, a drug intended to improve kidney function by controlling RAAS overactivation when used alongside ACE inhibitors or angiotensin receptor blockers.
The study is testing the drug finerenone, known as Kerendia, which is designed to enhance kidney function by reducing RAAS overactivity. This intervention is expected to work in conjunction with existing treatments like ACE inhibitors or ARBs.
This Phase 3 study is interventional, with a single-group assignment and no masking, focusing on treatment. Participants will receive finerenone for up to 18 months, with regular monitoring of health parameters.
The study began on November 8, 2022, with primary completion expected in 2025. The last update was submitted on August 6, 2025. These dates are crucial for tracking the study’s progress and anticipated results.
The study’s progress could influence Bayer’s stock performance positively, as successful outcomes may enhance the company’s market position in treating chronic kidney disease. Investors should watch for updates, as positive results could differentiate Bayer from competitors in the renal treatment market.
The study is ongoing, with further information available on the ClinicalTrials portal.